These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15254882)

  • 41. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.
    Lim EL; Hollingsworth KG; Smith FE; Thelwall PE; Taylor R
    Clin Sci (Lond); 2011 Aug; 121(4):169-77. PubMed ID: 21388348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of acipimox on plasma lipids and glucose/insulin in pregnant rats.
    Sánchez-Vera I; Bonet B; Viana M; Herrera E; Indart A
    Int J Exp Diabetes Res; 2002; 3(4):233-9. PubMed ID: 12546276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.
    Rigazio S; Lehto HR; Tuunanen H; Någren K; Kankaanpaa M; Simi C; Borra R; Naum AG; Parkkola R; Knuuti J; Nuutila P; Iozzo P
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E413-9. PubMed ID: 18505832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of acipimox on the lipolysis rate in subcutaneous adipose tissue of obese subjects.
    Flechtner-Mors M; Jenkinson CP; Alt A; Adler G; Ditschuneit HH
    Diabetes Metab Res Rev; 2001; 17(5):387-90. PubMed ID: 11747144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationships of plasma leptin levels to changes in plasma free fatty acids in women who are lean and women who are abdominally obese.
    Hennes MM; Dua A; Maas DL; Sonnenberg GE; Krakower GR; Kissebah AH
    Obes Res; 1997 Sep; 5(5):442-6. PubMed ID: 9385619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    Worm D; Vinten J; Vaag A; Henriksen JE; Beck-Nielsen H
    Eur J Endocrinol; 2000 Sep; 143(3):389-95. PubMed ID: 11022182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of hepatic glycogen content on hepatic insulin action in humans: alteration in the relative contributions of glycogenolysis and gluconeogenesis to endogenous glucose production.
    Wise S; Nielsen M; Rizza R
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1828-33. PubMed ID: 9177391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic consequences of fasting in old lean and obese Zucker rats.
    Triscari J; Bryce GF; Sullivan AC
    Metabolism; 1980 Apr; 29(4):377-85. PubMed ID: 6990175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The actions of dichloroacetic acid on blood glucose, liver glycogen and fatty acid synthesis in obese-hyperglycaemic (ob/ob) and lean mice.
    Enser M; Whittington FM
    Horm Metab Res; 1983 May; 15(5):225-9. PubMed ID: 6347856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
    Carey PE; Gerrard J; Cline GW; Dalla Man C; English PT; Firbank MJ; Cobelli C; Taylor R
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E941-7. PubMed ID: 15998660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
    Fulcher GR; Walker M; Catalano C; Farrer M; Alberti KG
    Clin Sci (Lond); 1992 May; 82(5):565-71. PubMed ID: 1317767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
    Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis.
    Farrer M; Fulcher GR; Johnson AJ; Record CO; Alberti KG
    Metabolism; 1992 May; 41(5):465-70. PubMed ID: 1588824
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carbohydrate metabolism in lean and obese Zucker rats.
    Triscari J; Stern JS; Johnson PR; Sullivan AC
    Metabolism; 1979 Feb; 28(2):183-9. PubMed ID: 763152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.